> Take me to the Patient area

Patient Info

Lecicarbon Suppository Prescribing information (please refer to the SmPCs before prescribing)

Indications Short term treatment of constipation due to various causes (e.g. nutrition poor in fibres, lack of physical activity, as well as diseases requiring easy defaecation). Emptying the colon before diagnostic or therapeutic procedures in the rectum. Lecicarbon® A Suppository is suitable for adults and children over 12 years of age. Lecicarbon® C Suppository is suitable for children under 12 years of age. Available Strengths: Lecicarbon contains sodium hydrogen carbonate (Lecicarbon A: 0.50g per suppository; Lecicarbon C: 0.25g per suppository) and sodium dihydrogen phosphate (Lecicarbon A: 0.68g per suppository; Lecicarbon C: 0.34g per suppository). Dosage and method of use: Unless otherwise directed insert one suppository into the rectum when needed. If necessary, this can be repeated after 30-60 minutes. Contraindications: Lecicarbon must not be used in cases of ileus (intestinal obstruction), in case of all anal and rectal region diseases that can lead to an excessive absorption of carbon dioxide, especially in children and infants, and in the case of hypersensitivity to soybean, peanut or one of the excipients of Lecicarbon suppository. In the presence of toxic megacolon, the product should only be used with explicit permission of the treating physician. Side effects: Rarely Soya lecithin has been known to cause allergic reactions. The insertion of the suppository can very occasionally cause a slight burning sensation, which quickly disappears. MA number: Lecicarbon A: PL 28418/0001; Lecicarbon C: PL 28418/0002. Cost: £8.20 pack of 10. MAH: athenstaedt GmbH & Co KG, Am Beerberg 1, 35088 Battenberg, Germany. Distributed by: Aspire Pharma Ltd, Unit 4, Rotherbrook Court, Bedford Road, Petersfield, GU32 3QG. Legal category: P. Version number: 1010222051 v 7.0 November 2020

For further information please call: 01730 231148,
email: [email protected] or visit

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Lecicarbon, please see the abbreviated prescribing information.
Revision reference – Lecicarbon_09_27/07/2020